出版國家:England
出版周期:季刊
影響因子:1.51
研究領域:個人健康服務、藥理學
5年影響因子:1.115
國外數(shù)據(jù)庫收錄:IM,1.51" />
醫(yī)學全在線
醫(yī)學全在線首頁-醫(yī)師-藥師-護士-衛(wèi)生資格-高級職稱-考試題庫-網(wǎng)校-考研-圖譜-下載-招聘  
分類
國家級省級浙江省各省雜志
科技核心北大核心CSCDCSCD擴展
工具
期刊知識寫作指導 論文投稿推薦期刊
期刊驗證論文檢測 錄用通知往期目錄
SCI
SCI指導影響因子
期刊點評基金動態(tài)
其它
經(jīng)濟教育計算機
建筑體育農(nóng)業(yè)
北京|天津|河北|山西|湖北|江蘇|安徽|山東|上海|浙江|江西|福建|湖南|寧夏|內(nèi)蒙古|河南
四川|重慶|貴州|云南|遼寧|吉林|廣東|廣西|海南|陜西|甘肅|新疆|青海|衛(wèi)生部直屬|黑龍江|兵團
您現(xiàn)在的位置: 醫(yī)學全在線 > 醫(yī)學論文 > SCI期刊 > 正文:Personalized medicine if:1.51
    

Personalized medicine


Personalized medicine
影響因子: 1.51
I S S N: 1741-0541
出 版 社: Future Medicine
出 版 地: London
出版國家: England
刊  期: 季刊
創(chuàng)刊時間: 2004
語  種: 英文
審稿周期: 較慢,6-12周
中科院分區(qū): 4
投稿命中率: 較易
國外數(shù)據(jù)庫收錄: IM
中國收錄文章數(shù):
5年影響因子: 1.115
研究領域: 個人健康服務、藥理學
官方鏈接: http://www.futuremedicine.com/loi/pme
投稿須知: http://www.futuremedicine.com/loi/pme

期刊介紹:

Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include: Advances in molecular diagnostics; Biochip/microarray technologies; Biological therapies or vaccine approaches at specific genetic and immunologic targets; Cost-benefit issues for personalized medicine; Ethics in personalized medicine; Impact of personalized medicine on healthcare and the pharmaceutical industry; Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics; Incorporation of genetic analysis in clinical trials methodology; Integration of diagnosis with therapy; Prediction of adverse reactions of drugs and drug safety; Treatment monitoring.
...
關于我們 - 聯(lián)系我們 -版權申明 -誠聘英才 - 網(wǎng)站地圖 - 網(wǎng)絡課程 - 幫助
醫(yī)學全在線 版權所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP備12017320號
百度大聯(lián)盟認證綠色會員實名網(wǎng)站 360認證可信網(wǎng)站 中網(wǎng)驗證